NASDAQ: AKTXAkari Therapeutics PLC Stock Ownership - Who owns Akari Therapeutics?
Insider buying vs selling
Have Akari Therapeutics PLC insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.
Be the first to know when AKTX insiders and whales buy or sell their stock.
AKTX Shareholders
What type of owners hold Akari Therapeutics PLC stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Raymond Prudochlebosz | 20.01% | 3,171,056,800 | $3.84B | Insider |
| Samir Rashmikant Patel | 13.16% | 2,085,237,500 | $2.52B | Insider |
| Ray Prudo | 4.56% | 722,345,600 | $874.04M | Insider |
| James Hill | 4.56% | 722,345,600 | $874.04M | Insider |
| Rpc Pharma Ltd | 4.56% | 722,345,600 | $874.04M | Insider |
| Stuart Ungar | 4.56% | 722,345,600 | $874.04M | Insider |
| Rachelle Suzanne Jacques | 3.40% | 538,457,900 | $651.53M | Insider |
| Donald A. Williams | 0.13% | 20,000,000 | $24.20M | Insider |
| Michael Grissinger | 0.13% | 20,000,000 | $24.20M | Insider |
| Mark S. Cohen | 0.01% | 1,055,600 | $1.28M | Insider |
AKTX vs Biotech Stocks
Akari Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.